# Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

> **NCT01121705** · PHASE3 · COMPLETED · sponsor: **Casa Sollievo della Sofferenza IRCCS** · enrollment: 360 (actual)

## Conditions studied

- Chronic Hepatitis

## Interventions

- **DRUG:** Peg Interferon alpha2b + Ribavirin

## Key facts

- **NCT ID:** NCT01121705
- **Lead sponsor:** Casa Sollievo della Sofferenza IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2011-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121705, "Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01121705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*